Aldeyra Therapeutics Receives Buy Rating from JonesTrading with $9.00 Price Target

Aldeyra Therapeutics (ALDX) received a Buy rating from JonesTrading analyst Catherine Novack, with a price target of $9.00. Novack has a 37.39% success rate on recommended stocks. The analyst consensus on ALDX is a Strong Buy with an average price target of $8.75. The company reported a quarterly GAAP net loss of $9.93 million, compared to $8.08 million last year.

Aldeyra Therapeutics Inc. (ALDX), a biotechnology company focused on immune-mediated and metabolic diseases, recently reported its Q2 2025 earnings. The company posted a quarterly GAAP net loss of $9.93 million, compared to $8.08 million in the same period last year. Despite the loss, analysts remain optimistic about Aldeyra's prospects.

Catherine Novack, a JonesTrading analyst, gave Aldeyra a Buy rating with a price target of $9.00. Novack's success rate on recommended stocks is 37.39%. The analyst consensus on ALDX is a Strong Buy, with an average price target of $8.75. Analysts expect a rise in quarterly revenue, with estimates suggesting revenue of $1.083 million for the period ending September 30, 2025 [2].

Aldeyra's financial health remains robust, with $90.1 million in cash, cash equivalents, and marketable securities as of May 14, 2025. The company believes this funding will be sufficient to support its operations through 2027. Aldeyra's pipeline includes several promising drug candidates, such as Reproxalap for dry eye disease and ADX-248 for moderate alcohol-associated hepatitis [1].

While Aldeyra reported a net loss, the company's strong financial position and promising pipeline have analysts bullish on its future prospects. The company continues to invest in innovative therapies that modulate protein systems, aiming to optimize multiple pathways while minimizing toxicity.

References:
[1] https://www.marketscreener.com/news/aldeyra-therapeutics-corporate-overview-8727b2-ce7c5edbdf8af326
[2] https://www.tradingview.com/news/reuters.com,2025:newsml_L8N3U03YH:0-aldeyra-therapeutics-inc-expected-to-post-a-loss-of-25-cents-a-share-earnings-preview/